WO2010017355A3 - Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux - Google Patents

Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux Download PDF

Info

Publication number
WO2010017355A3
WO2010017355A3 PCT/US2009/052949 US2009052949W WO2010017355A3 WO 2010017355 A3 WO2010017355 A3 WO 2010017355A3 US 2009052949 W US2009052949 W US 2009052949W WO 2010017355 A3 WO2010017355 A3 WO 2010017355A3
Authority
WO
WIPO (PCT)
Prior art keywords
maturation
small molecule
molecule inhibitors
retroviral assembly
assembly
Prior art date
Application number
PCT/US2009/052949
Other languages
English (en)
Other versions
WO2010017355A2 (fr
Inventor
Asim Kuman Debnath
Hongtao Zhang
Francesca Curreli
Original Assignee
New York Blood Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York Blood Center filed Critical New York Blood Center
Priority to CA2730064A priority Critical patent/CA2730064A1/fr
Priority to EP09791220A priority patent/EP2323660A2/fr
Priority to AU2009279616A priority patent/AU2009279616A1/en
Priority to JP2011522236A priority patent/JP5548197B2/ja
Publication of WO2010017355A2 publication Critical patent/WO2010017355A2/fr
Publication of WO2010017355A3 publication Critical patent/WO2010017355A3/fr
Priority to IL211111A priority patent/IL211111A/en
Priority to IL228831A priority patent/IL228831A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des composés chimiques qui perturbent l’assemblage et la maturation rétroviraux. Plus particulièrement, la présente invention concerne des composés à petite molécule qui perturbent la formation et la maturation de particules de virus et des procédés d’utilisation de telles petites molécules pour traiter l’infection par VIH-1.
PCT/US2009/052949 2008-08-08 2009-08-06 Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux WO2010017355A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA2730064A CA2730064A1 (fr) 2008-08-08 2009-08-06 Inhibiteurs a petite molecule d'assemblage et de maturation retroviraux
EP09791220A EP2323660A2 (fr) 2008-08-08 2009-08-06 Inhibiteurs à petite molécule d assemblage et de maturation rétroviraux
AU2009279616A AU2009279616A1 (en) 2008-08-08 2009-08-06 Small molecule inhibitors of retroviral assembly and maturation
JP2011522236A JP5548197B2 (ja) 2008-08-08 2009-08-06 レトロウイルスの集合及び成熟の小分子阻害剤
IL211111A IL211111A (en) 2008-08-08 2011-02-07 Use of small-molecule materials to make preparations with activity that inhibits the convergence and maturation of HIV virus
IL228831A IL228831A (en) 2008-08-08 2013-10-10 Materials that inhibit retrovirus convergence and maturation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8757408P 2008-08-08 2008-08-08
US61/087,574 2008-08-08

Publications (2)

Publication Number Publication Date
WO2010017355A2 WO2010017355A2 (fr) 2010-02-11
WO2010017355A3 true WO2010017355A3 (fr) 2010-05-27

Family

ID=41211879

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052949 WO2010017355A2 (fr) 2008-08-08 2009-08-06 Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux

Country Status (7)

Country Link
US (2) US8299093B2 (fr)
EP (2) EP2335779A1 (fr)
JP (2) JP5548197B2 (fr)
AU (1) AU2009279616A1 (fr)
CA (1) CA2730064A1 (fr)
IL (2) IL211111A (fr)
WO (1) WO2010017355A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011160206A1 (fr) 2010-06-23 2011-12-29 Morin Ryan D Biomarqueurs pour lymphomes non hodgkiniens et leurs utilisations
KR102373074B1 (ko) 2010-09-10 2022-03-11 에피자임, 인코포레이티드 인간 ｅｚｈ2의 억제제 및 이의 사용 방법
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
TWI598336B (zh) * 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
RU2658911C2 (ru) 2012-04-13 2018-06-26 Эпизайм, Инк. Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека
US10092572B2 (en) 2012-10-15 2018-10-09 Epizyme, Inc. Substituted benzene compounds
EA038869B1 (ru) 2013-10-16 2021-10-29 Эпизим, Инк. Кристаллические формы гидрохлорида n-((4,6-диметил-2-оксо-1,2-дигидропиридин-3-ил)метил)-5-(этил(тетрагидро-2h-пиран-4-ил)амино)-4-метил-4'-(морфолинометил)-[1,1'-бифенил]-3-карбоксамида, фармацевтические композиции на их основе и способы их применения
WO2015110999A1 (fr) * 2014-01-24 2015-07-30 Piramal Enterprises Limited Inhibiteurs de ezh2 et leurs utilisations
EP3327004B1 (fr) * 2015-07-17 2020-11-04 Fujifilm Corporation Composé hétérocyclique contenant de l'azote
WO2017040370A1 (fr) * 2015-09-03 2017-03-09 The Scripps Research Institute Inhibiteurs à petites molécules de la réplication du vih-1
EP3604281A4 (fr) * 2017-03-24 2020-08-19 Taisho Pharmaceutical Co., Ltd. Dérivé de 2(1h)-quinolinone
JP7336469B2 (ja) * 2017-09-08 2023-08-31 シムベリックス，インコーポレーティッド β－グルクロニダーゼを選択的に阻害し、薬物治療誘発性下痢に関連する副作用を緩和する化合物、組成物、及び方法
CA3179627A1 (fr) * 2020-05-27 2021-12-02 Aaron Coffin Benzamides substitues en tant que modulateurs de trex1
US20230365540A1 (en) * 2020-09-09 2023-11-16 The Regents Of The University Of California Small molecule inhibitors of enpp1
WO2023034413A2 (fr) * 2021-08-31 2023-03-09 The Regents Of The University Of California Procédés et agents pour moduler la réponse immunitaire

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010456A2 (fr) * 1999-08-09 2001-02-15 Tripep Ab Peptides bloquant les infections virales et procedes d'utilisation correspondants
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
US20030228573A1 (en) * 2002-04-22 2003-12-11 Summers Michael F. Antiviral inhibition of capsid proteins
WO2007008541A2 (fr) * 2005-07-08 2007-01-18 Kalypsys, Inc. Modificateurs d'absorption de cholesterol cellulaire
WO2007048042A2 (fr) * 2005-10-21 2007-04-26 University Of Alabama At Birmingham Inhibiteurs de petites molecules d'ensemble capside de vih-1
WO2007136592A2 (fr) * 2006-05-18 2007-11-29 Amphora Discovery Corporation Compositions à base de quinolones substituées et leurs utilisations
WO2008113006A1 (fr) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2A (en) * 1826-12-15 1836-07-29 mode of manufacturing wool or other fibrous materials
DE102005033327A1 (de) 2005-07-16 2007-01-25 Roche Diagnostics Gmbh Medizinisches Testgerät und Verfahren zur optischen Untersuchung eines Analyten
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
EP2291392B1 (fr) 2008-05-28 2014-03-05 New York Blood Center Molécules bifonctionnelles destinées à inhiber la pénétration du vih

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001010456A2 (fr) * 1999-08-09 2001-02-15 Tripep Ab Peptides bloquant les infections virales et procedes d'utilisation correspondants
US6455670B1 (en) * 2001-09-06 2002-09-24 Tripep Ab Pentamer peptide amide, ALGPG-NH2, that inhibits viral infectivity and methods of use thereof
US20030228573A1 (en) * 2002-04-22 2003-12-11 Summers Michael F. Antiviral inhibition of capsid proteins
WO2007008541A2 (fr) * 2005-07-08 2007-01-18 Kalypsys, Inc. Modificateurs d'absorption de cholesterol cellulaire
WO2007048042A2 (fr) * 2005-10-21 2007-04-26 University Of Alabama At Birmingham Inhibiteurs de petites molecules d'ensemble capside de vih-1
WO2007136592A2 (fr) * 2006-05-18 2007-11-29 Amphora Discovery Corporation Compositions à base de quinolones substituées et leurs utilisations
WO2008113006A1 (fr) * 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Procédés d'utilisation de composés à base de quinolinone dans le traitement des maladies ou des affections associées aux canaux sodiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BADAWEY E ET AL: "Benzimidazole condensed ring system. IX. Potential antineoplastics. New synthesis of some pyrido[1,2-a]benzimidazoles and related derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 30, no. 4, 1 January 1995 (1995-01-01), pages 327 - 332, XP004040151, ISSN: 0223-5234 *

Also Published As

Publication number Publication date
JP2011530528A (ja) 2011-12-22
US8546439B2 (en) 2013-10-01
JP2013216693A (ja) 2013-10-24
US20100035912A1 (en) 2010-02-11
US20130004458A1 (en) 2013-01-03
IL211111A (en) 2014-05-28
IL211111A0 (en) 2011-04-28
WO2010017355A2 (fr) 2010-02-11
IL228831A (en) 2014-06-30
JP5548197B2 (ja) 2014-07-16
CA2730064A1 (fr) 2010-02-11
EP2335779A1 (fr) 2011-06-22
AU2009279616A1 (en) 2010-02-11
EP2323660A2 (fr) 2011-05-25
US8299093B2 (en) 2012-10-30
IL228831A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
WO2010017355A3 (fr) Inhibiteurs à petite molécule d’assemblage et de maturation rétroviraux
WO2012034116A3 (fr) Petites molécules à titre de modulateurs épigénétiques de la déméthylase 1 spécifique de la lysine et méthodes de traitement de troubles
WO2009152356A3 (fr) Composés et compositions utiles pour le traitement de la malaria
WO2009111676A8 (fr) Petites molécules contenant du bore utilisées en tant qu'agents anti-inflammatoires
AU2016204248A1 (en) Boron-Containing Molecules
WO2008134761A3 (fr) Modification des groupes de ciblage biologiques pour le traitement du cancer
WO2007095638A3 (fr) Petites molecules contenant du bore en tant qu'agents anti-inflammatoires
WO2007048042A3 (fr) Inhibiteurs de petites molecules d'ensemble capside de vih-1
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
WO2008134646A3 (fr) Suppression de l'interférence par l'arn des maladies neurodégénératives et ses méthodes d'utilisation
WO2009156462A3 (fr) Composés organiques
EA201170295A1 (ru) ИНГИБИТОРЫ сМЕТ
AU2008257801A8 (en) RSV-specific binding molecules and means for producing them
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
AU2009236256A8 (en) Small molecule inhibitors of the pleckstrin homology domain and methods for using same
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
ATE486896T1 (de) Colöserfreie, selbstvernetzende pur-dispersionen
WO2009039189A3 (fr) Compositions comprenant des arnsi de stat3 et leurs procédés d'utilisation
WO2010011343A3 (fr) Procédés de traitement d’affections virales
WO2010021717A3 (fr) Inhibiteurs de la protéase du vhc
WO2008101160A3 (fr) Modulateurs de htra1-pdz et de htra3-pdz
WO2012103810A1 (fr) Certaines entités chimiques, compositions et procédés
WO2009067191A3 (fr) Procédés et compositions pour le traitement d'une infection par le virus de l'hépatite c (vhc)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09791220

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009279616

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011522236

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2730064

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009279616

Country of ref document: AU

Date of ref document: 20090806

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2009791220

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009791220

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 211111

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE